Emma Pennington, Pharm.D., Ph.D., is a Senior Manager of Health Economics and Outcomes Research at Inovalon, where she leads real-world evidence (RWE) studies for leading pharmaceutical companies and emerging biotech organizations. She combines clinical training as a pharmacist with advanced experience in observational study design and real-world data (RWD) analytics to help clients generate rigorous, decision-ready evidence.
Emma’s work spans multiple therapeutic areas, with a particular focus on pregnancy and maternal health. She is frequently engaged for studies involving complex patient populations and longitudinal treatment patterns, leveraging innovative analytical approaches to deliver meaningful insights regarding market access, clinical strategy, and quality improvement. Her research has been published in leading peer-reviewed journals and presented at major scientific conferences. Prior to Inovalon, Emma held analytic roles at AbbVie and Ascension Health and contributed to product development at the National Committee for Quality Assurance (NCQA).
Emma earned her Pharm.D. and Ph.D. in Pharmaceutical Sciences from the University of Texas at Austin College of Pharmacy.
Treatment Patterns Among Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD): A Real-World Evidence Study
Accepted for presentation at Consortium of Multiple Sclerosis Centers (CMSC) 2026 Annual Meeting. Findings available upon request. Contact us for more information.
Predictors of Timely Hypertension Treatment Escalation in the United States: Results from the Real-World BREAKTHROUGH Patient Registry
Accepted for presentation at American College of Cardiology (ACC.26). Findings available upon request. Contact us for more information.